paclitaxel liposome + trastuzumab + pertuzumab

This combination treatment regimen is being evaluated as a first-line salvage therapy for patients with HER2-positive advanced breast cancer. It consists of paclitaxel liposome, a liposomal formulation of the taxane chemotherapy agent paclitaxel, administered in conjunction with anti-HER2 monoclonal antibodies such as trastuzumab and pertuzumab (or alternatives like pyrotinib). Paclitaxel liposome functions by binding to and stabilizing microtubules, which prevents their disassembly and leads to cell cycle arrest in the G2/M phase and subsequent apoptosis. The anti-HER2 antibodies target the extracellular domain of the Human Epidermal Growth Factor Receptor 2 (HER2), inhibiting downstream proliferative signaling pathways (such as PI3K/AKT) and recruiting immune effector cells to induce antibody-dependent cellular cytotoxicity (ADCC). This regimen is the subject of a retrospective real-world study conducted by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences to assess its efficacy and safety profile in clinical practice settings.

Other names

paclitaxel liposome + anti-HER2 monoclonal antibodyfirst line treatment-Cancer Institute and Hospital, Chinese Academy of Medical Sciences-breast cancerpaclitaxel liposome + trastuzumabpaclitaxel liposome + trastuzumab + pertuzumab + pyrotinib